ADVM Earnings — Adverum Biotechnologies, Inc. Common Stock Post-ER Performance | BigEarnings
ADVM — Adverum Biotechnologies, Inc. Common Stock
XNAS
Price$4.32
Market Cap$95.0M
P/E—
52W Range$1.78 – $8.18
About Adverum Biotechnologies, Inc. Common Stock
Adverum Biotechnologies Inc is a clinical-stage company that aims to establish gene therapy as a new standard of care for prevalent ocular diseases. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (VEGF) IVT injections.
